Have a feature idea you'd love to see implemented?
Let us know!
MDWD MediWound Ltd
Price (delayed)
$16.49
Market cap
$173.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.9
Enterprise value
$134.23M
mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe
Highlights
The equity has surged by 92% since the previous quarter and by 3.6% year-on-year
The company's quick ratio rose by 31% QoQ but it fell by 30% YoY
The net income has plunged by 126% YoY and by 40% from the previous quarter
MDWD's gross profit has dropped by 78% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of MDWD
Market
Valuations
Earnings
Shares outstanding
10.51M
Market cap
$173.33M
Enterprise value
$134.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.47
Price to sales (P/S)
8.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
Revenue
$19.72M
Gross profit
$2.45M
Net income
-$28.06M
EBIT
-$16.61M
EBITDA
-$15.18M
Free cash flow
-$22.28M
Per share
Balance sheet
Liquidity
EPS
-$2.9
EPS diluted
-$2.9
Free cash flow per share
-$2.12
Book value per share
$3.69
Revenue per share
$1.88
TBVPS
$7.1
Total assets
$74.73M
Total liabilities
$40.5M
Debt
$6.46M
Equity
$34.24M
Working capital
$28.31M
Debt to equity
0.19
Current ratio
2.11
Quick ratio
1.99
Net debt/EBITDA
2.58
Margins
Efficiency
Dividend
EBITDA margin
-77%
Gross margin
12.4%
Net margin
-142.3%
Operating margin
-87.1%
Return on assets
-43%
Return on equity
-105%
Return on invested capital
-94%
Return on capital employed
-33.8%
Return on sales
-84.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDWD stock price
How has the MediWound stock price performed over time
Intraday
-4.13%
1 week
-4.63%
1 month
-1.73%
1 year
58.25%
YTD
62.14%
QTD
-8.69%
Financial performance
How have MediWound's revenue and profit performed over time
Revenue
$19.72M
Gross profit
$2.45M
Operating income
-$17.18M
Net income
-$28.06M
Gross margin
12.4%
Net margin
-142.3%
MediWound's net margin has shrunk by 186% YoY and by 43% QoQ
The company's operating margin has shrunk by 139% YoY and by 14% QoQ
The net income has plunged by 126% YoY and by 40% from the previous quarter
MDWD's operating income has shrunk by 88% YoY and by 12% QoQ
Growth
What is MediWound's growth rate over time
Valuation
What is MediWound stock price valuation
P/E
N/A
P/B
4.47
P/S
8.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
The EPS has dropped by 65% year-on-year and by 34% since the previous quarter
The equity has surged by 92% since the previous quarter and by 3.6% year-on-year
MDWD's P/B is 65% below its 5-year quarterly average of 12.6 and 17% below its last 4 quarters average of 5.4
The P/S is 104% higher than the 5-year quarterly average of 4.3 and 24% higher than the last 4 quarters average of 7.1
MediWound's revenue has decreased by 21% YoY and by 2.1% from the previous quarter
Efficiency
How efficient is MediWound business performance
MDWD's ROE has shrunk by 137% YoY and by 39% QoQ
MDWD's ROIC has dropped by 126% year-on-year and by 14% since the previous quarter
The ROA has plunged by 116% YoY and by 36% from the previous quarter
The return on sales has declined by 16% since the previous quarter
Dividends
What is MDWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDWD.
Financial health
How did MediWound financials performed over time
The company's total assets is 85% higher than its total liabilities
MDWD's current ratio is down by 31% year-on-year but it is up by 28% since the previous quarter
The company's quick ratio rose by 31% QoQ but it fell by 30% YoY
MediWound's debt is 81% lower than its equity
The equity has surged by 92% since the previous quarter and by 3.6% year-on-year
MediWound's debt to equity has decreased by 47% QoQ but it has increased by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.